-
-
Toggle navigation
Frontiers journals are at the top of citation and impact metrics
in Oncology |
|
Submit your manuscript
Scope
This section aims to publish significant clinical and basic research findings on all aspects related to hematologic oncology, including the areas of acute and chronic leukemias, lymphomas and Hodgkin’s disease, plasma cell disorders, and stem cell transplantation. Specifically, we welcome papers on the following topics: 1) identification of genes and genetic variants related to the pathophysiology of hematologic malignancies; 2) characterization of genes and biological pathways implicated in the genesis and progression of hematologic malignancies; 3) translational studies bridging the areas of basic and clinical research; 4) phase I clinical studies demonstrating clinical applications of novel therapeutic approaches; 5) clinical studies with the potential to promote novel aspects of the treatment of patients with hematologic malignancies; and 6) determination of how chemotherapeutic and immunologic agents and other targeted molecules exert their effects. While Hematology Oncology is primarily centered on human studies, in vitro and animal studies that are closely related to research on humans are also welcome. Our ultimate goal is to accelerate the communication in the field and stimulate clinical applications of advances in molecular research.Indexed in: PubMed, PubMed Central, Scopus, Google Scholar, DOAJ, CrossRef, Chemical Abstracts Service (CAS), Science Citation Index Expanded, CLOCKSS
PMCID: all published articles receive a PMCID
Hematologic Malignancies welcomes submissions of the following article types: Case Report, Clinical Trial, Correction, Editorial, Hypothesis and Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Review, Specialty Grand Challenge, Systematic Review and Technology Report.
All manuscripts must be submitted directly to the section Hematologic Malignancies, where they are peer-reviewed by the Associate and Review Editors of the specialty section.
Articles published in the section Hematologic Malignancies will benefit from the Frontiers impact and tiering system after online publication. Authors of published original research with the highest impact, as judged democratically by the readers, will be invited by the Chief Editor to write a Frontiers Focused Review - a tier-climbing article. This is referred to as "democratic tiering". The author selection is based on article impact analytics of original research published in all Frontiers specialty journals and sections. Focused Reviews are centered on the original discovery, place it into a broader context, and aim to address the wider community across all of Oncology.
Frontiers Editorial Office
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Switzerland
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
Frontiers Support
Tel +41(0)21 510 17 10
Fax +41 (0)21 510 17 01
support@frontiersin.org
There are no results to display.
Click on any of the keywords to find further editors related to it.
- Article(s) found
- Latest
- Most viewed
This section has no articles.
There are no articles to display. Please try changing the filters.
- Research Topic(s) found
- Latest
- Most viewed
Contact Editorial Office
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Switzerland
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
For all queries regarding manuscripts in Review and potential conflicts of interest, please contact oncology.editorial.office@frontiersin.org
For queries regarding Research Topics, Editorial Board applications, and journal development, please contact oncology@frontiersin.org
Tel +41(0)21 510 17 10
Fax +41 (0)21 510 17 01
For technical issues, please visit our Frontiers Help Center, or contact our IT HelpDesk team at support@frontiersin.org